June 2011 Newsletter

June 26, 2011:

FDA Drug Advisory Committee Recommends Approval of Regeneron’s VEGF Trap-Eye for Wet AMD

The FDA advisory panel recommended approval of Regeneron’s VEGF Trap-Eye for wet AMD. The fusion protein is likely to become a serious challenger to Genentech’s Lucentis and off-label IVT Avastin.

June 26, 2011:

US Premium IOL Procedures Climb in Q1-2011

Premium IOL procedures approached 15 percent of all US IOL procedures during Q1-2011.

June 26, 2011:

Refractive Surgery Shows Weak Improvement in Q1-2011

In Q1-2011, refractive surgeries showed rather anemic improvement, as the consumer confidence index again dipped during this protracted recession.

June 26, 2011:

Is LASIK Yesterday’s Technology or is it Poised for Recovery?

Is LASIK yesterday’s technology or is it poised for recovery? Both arguments raise valid issues.

June 26, 2011:

Laser Refractive Cataract Surgery to Expand Cataract Equipment Market

Our new 2011 Comprehensive Report on the Global Cataract Equipment Market forecasts the five-year impact of laser refractive cataract surgery in wealthier nations and the conversion to ultrasonic phaco in emerging markets.

June 26, 2011:

June 2011 News Briefs

This month's news includes the latest from CROMA, Bausch & Lomb, Merge Healthcare, Ophthalmic Imaging Systems, Alcon, NovaBay Pharmaceuticals, Pfizer and pSivida.

Social media